Journal
MINI-REVIEWS IN MEDICINAL CHEMISTRY
Volume 18, Issue 15, Pages 1294-1301Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389557517666170208142254
Keywords
Anti-tyrosinase activity; aryl butenes; chronic myeloid leukemia; ferrociphenol; hydroxytamoxifen; imatinib; skin depigmentation
Categories
Funding
- Ministry of Higher Education and Scientific Research of Tunisia
- Agence Nationale de la Recherche
Ask authors/readers for more resources
Background & Objective: The inhibitory effects of four series of aryl butene derivatives, active against breast cancer, on the monophenolase activity of tyrosinase, in melanin-free ink from Sepia officinalis, have been studied. Hydroxytamoxifen 1, ferrociphenol 17 and several aryl butene analogs have shown strong antiproliferative activity on hormone-dependent and hormone-independent breast cancer cells and were evaluated in leukemia K562 cell proliferation. Their potential to induce skin depigmentation by evaluating their anti-tyrosinase activity was also estimated. In order to better rationalize the tyrosinase inhibitory action and the binding mode of the compounds, docking studies were carried out. Conclusion: Hydroxytamoxifen and some aryl butenes showed strong antiproliferative effects against K562 cells at 1 mu M without showing tyrosinase inhibition. If phenolic compounds 16 and 17 showed the best antiproliferative activity on K562, Hydroxytamoxifen and compounds 5, 10, 20 and 21 have been identified as candidates for further development against chronic myeloid leukemia (CML), and are predicted to not induce depigmentation of the skin, a side effect encountered with imatinib, conventionally used for the treatment of CML.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available